JP2012524085A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012524085A5 JP2012524085A5 JP2012506006A JP2012506006A JP2012524085A5 JP 2012524085 A5 JP2012524085 A5 JP 2012524085A5 JP 2012506006 A JP2012506006 A JP 2012506006A JP 2012506006 A JP2012506006 A JP 2012506006A JP 2012524085 A5 JP2012524085 A5 JP 2012524085A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- structural formula
- deuterium
- group
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 69
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 13
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 12
- 229910052805 deuterium Inorganic materials 0.000 claims 12
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims 10
- 229910052739 hydrogen Inorganic materials 0.000 claims 10
- 239000002904 solvent Substances 0.000 claims 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 9
- 239000001257 hydrogen Substances 0.000 claims 9
- -1 CYP39 Proteins 0.000 claims 8
- XLYOFNOQVPJJNP-ZSJDYOACSA-N Heavy water Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 claims 8
- 238000000034 method Methods 0.000 claims 7
- 125000006239 protecting group Chemical group 0.000 claims 5
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 5
- 239000003638 chemical reducing agent Substances 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 230000036470 plasma concentration Effects 0.000 claims 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- 239000012321 sodium triacetoxyborohydride Substances 0.000 claims 4
- VEXZGXHMUGYJMC-DYCDLGHISA-N Deuterium chloride Chemical compound [2H]Cl VEXZGXHMUGYJMC-DYCDLGHISA-N 0.000 claims 3
- 239000002253 acid Substances 0.000 claims 3
- 239000002207 metabolite Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 108010082126 Alanine transaminase Proteins 0.000 claims 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 claims 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 claims 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 claims 2
- 108010026925 Cytochrome P-450 CYP2C19 Proteins 0.000 claims 2
- 108010000561 Cytochrome P-450 CYP2C8 Proteins 0.000 claims 2
- 108010000543 Cytochrome P-450 CYP2C9 Proteins 0.000 claims 2
- 108010001237 Cytochrome P-450 CYP2D6 Proteins 0.000 claims 2
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 claims 2
- 102100029363 Cytochrome P450 2C19 Human genes 0.000 claims 2
- 102100029359 Cytochrome P450 2C8 Human genes 0.000 claims 2
- 102100029358 Cytochrome P450 2C9 Human genes 0.000 claims 2
- 102100021704 Cytochrome P450 2D6 Human genes 0.000 claims 2
- 102000018832 Cytochromes Human genes 0.000 claims 2
- 108010052832 Cytochromes Proteins 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- 102000010909 Monoamine Oxidase Human genes 0.000 claims 2
- 108010062431 Monoamine oxidase Proteins 0.000 claims 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims 2
- 102000001708 Protein Isoforms Human genes 0.000 claims 2
- 108010029485 Protein Isoforms Proteins 0.000 claims 2
- 108010022037 Retinoic Acid 4-Hydroxylase Proteins 0.000 claims 2
- 206010052779 Transplant rejections Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 claims 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 210000004185 liver Anatomy 0.000 claims 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 210000002966 serum Anatomy 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 102100027518 1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial Human genes 0.000 claims 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 claims 1
- 108010073030 25-Hydroxyvitamin D3 1-alpha-Hydroxylase Proteins 0.000 claims 1
- 102100036285 25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial Human genes 0.000 claims 1
- 102000004008 5'-Nucleotidase Human genes 0.000 claims 1
- 102100032645 7-alpha-hydroxycholest-4-en-3-one 12-alpha-hydroxylase Human genes 0.000 claims 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 claims 1
- 108010078554 Aromatase Proteins 0.000 claims 1
- 102100029361 Aromatase Human genes 0.000 claims 1
- 101000856500 Bacillus subtilis subsp. natto Glutathione hydrolase proenzyme Proteins 0.000 claims 1
- 102000004506 Blood Proteins Human genes 0.000 claims 1
- 108010017384 Blood Proteins Proteins 0.000 claims 1
- 108010084976 Cholesterol Side-Chain Cleavage Enzyme Proteins 0.000 claims 1
- 102100027516 Cholesterol side-chain cleavage enzyme, mitochondrial Human genes 0.000 claims 1
- 108010009911 Cytochrome P-450 CYP11B2 Proteins 0.000 claims 1
- 108010074918 Cytochrome P-450 CYP1A1 Proteins 0.000 claims 1
- 108010074922 Cytochrome P-450 CYP1A2 Proteins 0.000 claims 1
- 108010020070 Cytochrome P-450 CYP2B6 Proteins 0.000 claims 1
- 108010001202 Cytochrome P-450 CYP2E1 Proteins 0.000 claims 1
- 102100024332 Cytochrome P450 11B1, mitochondrial Human genes 0.000 claims 1
- 102100024329 Cytochrome P450 11B2, mitochondrial Human genes 0.000 claims 1
- 102100031476 Cytochrome P450 1A1 Human genes 0.000 claims 1
- 102100026533 Cytochrome P450 1A2 Human genes 0.000 claims 1
- 102100027417 Cytochrome P450 1B1 Human genes 0.000 claims 1
- 102100039282 Cytochrome P450 26A1 Human genes 0.000 claims 1
- 102100039281 Cytochrome P450 26B1 Human genes 0.000 claims 1
- 102100038742 Cytochrome P450 2A13 Human genes 0.000 claims 1
- 102100036194 Cytochrome P450 2A6 Human genes 0.000 claims 1
- 102100038739 Cytochrome P450 2B6 Human genes 0.000 claims 1
- 102100029368 Cytochrome P450 2C18 Human genes 0.000 claims 1
- 102100024889 Cytochrome P450 2E1 Human genes 0.000 claims 1
- 102100031461 Cytochrome P450 2J2 Human genes 0.000 claims 1
- 102100026515 Cytochrome P450 2S1 Human genes 0.000 claims 1
- 102100039205 Cytochrome P450 3A4 Human genes 0.000 claims 1
- 102100039208 Cytochrome P450 3A5 Human genes 0.000 claims 1
- 102100039203 Cytochrome P450 3A7 Human genes 0.000 claims 1
- 102100027567 Cytochrome P450 4A11 Human genes 0.000 claims 1
- 102100027419 Cytochrome P450 4B1 Human genes 0.000 claims 1
- 102100024916 Cytochrome P450 4F11 Human genes 0.000 claims 1
- 102100024918 Cytochrome P450 4F12 Human genes 0.000 claims 1
- 102100024902 Cytochrome P450 4F2 Human genes 0.000 claims 1
- 102100024901 Cytochrome P450 4F3 Human genes 0.000 claims 1
- 102100024899 Cytochrome P450 4F8 Human genes 0.000 claims 1
- 102100022027 Cytochrome P450 4X1 Human genes 0.000 claims 1
- 102100022034 Cytochrome P450 4Z1 Human genes 0.000 claims 1
- 102100038637 Cytochrome P450 7A1 Human genes 0.000 claims 1
- 102100038698 Cytochrome P450 7B1 Human genes 0.000 claims 1
- 108010036233 Cytochrome P450 Family 46 Proteins 0.000 claims 1
- 102000023526 Cytochrome P450 Family 46 Human genes 0.000 claims 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims 1
- 206010013774 Dry eye Diseases 0.000 claims 1
- 102000001390 Fructose-Bisphosphate Aldolase Human genes 0.000 claims 1
- 108010068561 Fructose-Bisphosphate Aldolase Proteins 0.000 claims 1
- 108020004206 Gamma-glutamyltransferase Proteins 0.000 claims 1
- 101000861278 Homo sapiens 1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial Proteins 0.000 claims 1
- 101000725164 Homo sapiens Cytochrome P450 1B1 Proteins 0.000 claims 1
- 101000957389 Homo sapiens Cytochrome P450 2A13 Proteins 0.000 claims 1
- 101000875170 Homo sapiens Cytochrome P450 2A6 Proteins 0.000 claims 1
- 101000919360 Homo sapiens Cytochrome P450 2C18 Proteins 0.000 claims 1
- 101000941723 Homo sapiens Cytochrome P450 2J2 Proteins 0.000 claims 1
- 101000855328 Homo sapiens Cytochrome P450 2S1 Proteins 0.000 claims 1
- 101000745715 Homo sapiens Cytochrome P450 3A7 Proteins 0.000 claims 1
- 101000725111 Homo sapiens Cytochrome P450 4A11 Proteins 0.000 claims 1
- 101000909111 Homo sapiens Cytochrome P450 4F11 Proteins 0.000 claims 1
- 101000909108 Homo sapiens Cytochrome P450 4F12 Proteins 0.000 claims 1
- 101000909122 Homo sapiens Cytochrome P450 4F2 Proteins 0.000 claims 1
- 101000909121 Homo sapiens Cytochrome P450 4F3 Proteins 0.000 claims 1
- 101000909112 Homo sapiens Cytochrome P450 4F8 Proteins 0.000 claims 1
- 101000896935 Homo sapiens Cytochrome P450 4Z1 Proteins 0.000 claims 1
- 101000957672 Homo sapiens Cytochrome P450 7A1 Proteins 0.000 claims 1
- 101000957674 Homo sapiens Cytochrome P450 7B1 Proteins 0.000 claims 1
- 101000861263 Homo sapiens Steroid 21-hydroxylase Proteins 0.000 claims 1
- 101000875401 Homo sapiens Sterol 26-hydroxylase, mitochondrial Proteins 0.000 claims 1
- 101000653005 Homo sapiens Thromboxane-A synthase Proteins 0.000 claims 1
- 101000855326 Homo sapiens Vitamin D 25-hydroxylase Proteins 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 102000006500 Janus Kinase 3 Human genes 0.000 claims 1
- 108010019421 Janus Kinase 3 Proteins 0.000 claims 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims 1
- 102100021695 Lanosterol 14-alpha demethylase Human genes 0.000 claims 1
- 101710146773 Lanosterol 14-alpha demethylase Proteins 0.000 claims 1
- 102000002704 Leucyl aminopeptidase Human genes 0.000 claims 1
- 108010004098 Leucyl aminopeptidase Proteins 0.000 claims 1
- 108090000279 Peptidyltransferases Proteins 0.000 claims 1
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 claims 1
- 102100033075 Prostacyclin synthase Human genes 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 102100026372 Putative inactive cytochrome P450 2G1 Human genes 0.000 claims 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims 1
- 108010049356 Steroid 11-beta-Hydroxylase Proteins 0.000 claims 1
- 108010058254 Steroid 12-alpha-Hydroxylase Proteins 0.000 claims 1
- 108010015330 Steroid 17-alpha-Hydroxylase Proteins 0.000 claims 1
- 102100021719 Steroid 17-alpha-hydroxylase/17,20 lyase Human genes 0.000 claims 1
- 102100027545 Steroid 21-hydroxylase Human genes 0.000 claims 1
- 102100036325 Sterol 26-hydroxylase, mitochondrial Human genes 0.000 claims 1
- 102100030973 Thromboxane-A synthase Human genes 0.000 claims 1
- 102100026523 Vitamin D 25-hydroxylase Human genes 0.000 claims 1
- 239000000362 adenosine triphosphatase inhibitor Substances 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 229910021529 ammonia Inorganic materials 0.000 claims 1
- 229940035676 analgesics Drugs 0.000 claims 1
- 150000003931 anilides Chemical class 0.000 claims 1
- 239000000730 antalgic agent Substances 0.000 claims 1
- 239000003435 antirheumatic agent Substances 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 239000003054 catalyst Substances 0.000 claims 1
- 230000007012 clinical effect Effects 0.000 claims 1
- 108010026647 cytochrome P-450 4X1 Proteins 0.000 claims 1
- 108010062869 cytochrome P-450 CYP2G1 Proteins 0.000 claims 1
- 108010018719 cytochrome P-450 CYP4B1 Proteins 0.000 claims 1
- 239000012024 dehydrating agents Substances 0.000 claims 1
- 230000006866 deterioration Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 claims 1
- 239000007789 gas Substances 0.000 claims 1
- 230000005176 gastrointestinal motility Effects 0.000 claims 1
- 239000003862 glucocorticoid Substances 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 229940125721 immunosuppressive agent Drugs 0.000 claims 1
- 239000012280 lithium aluminium hydride Substances 0.000 claims 1
- 238000012317 liver biopsy Methods 0.000 claims 1
- 230000004060 metabolic process Effects 0.000 claims 1
- 150000004702 methyl esters Chemical class 0.000 claims 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 claims 1
- 229910000027 potassium carbonate Inorganic materials 0.000 claims 1
- 108010064377 prostacyclin synthetase Proteins 0.000 claims 1
- 108010043671 prostatic acid phosphatase Proteins 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 239000012312 sodium hydride Substances 0.000 claims 1
- 229910000104 sodium hydride Inorganic materials 0.000 claims 1
- 229940037128 systemic glucocorticoids Drugs 0.000 claims 1
- 238000002604 ultrasonography Methods 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17085809P | 2009-04-20 | 2009-04-20 | |
| US61/170,858 | 2009-04-20 | ||
| US30088710P | 2010-02-03 | 2010-02-03 | |
| US61/300,887 | 2010-02-03 | ||
| PCT/US2010/031773 WO2010123919A2 (en) | 2009-04-20 | 2010-04-20 | Piperidine inhibitors of janus kinase 3 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015037398A Division JP5932080B2 (ja) | 2009-04-20 | 2015-02-26 | ヤヌスキナーゼ３のピペリジンインヒビター |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012524085A JP2012524085A (ja) | 2012-10-11 |
| JP2012524085A5 true JP2012524085A5 (enExample) | 2013-06-06 |
| JP5709276B2 JP5709276B2 (ja) | 2015-04-30 |
Family
ID=43011721
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012506006A Active JP5709276B2 (ja) | 2009-04-20 | 2010-04-20 | ヤヌスキナーゼ３のピペリジンインヒビター |
| JP2015037398A Active JP5932080B2 (ja) | 2009-04-20 | 2015-02-26 | ヤヌスキナーゼ３のピペリジンインヒビター |
| JP2016084849A Active JP6145534B2 (ja) | 2009-04-20 | 2016-04-20 | ヤヌスキナーゼ３のピペリジンインヒビター |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015037398A Active JP5932080B2 (ja) | 2009-04-20 | 2015-02-26 | ヤヌスキナーゼ３のピペリジンインヒビター |
| JP2016084849A Active JP6145534B2 (ja) | 2009-04-20 | 2016-04-20 | ヤヌスキナーゼ３のピペリジンインヒビター |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US8299084B2 (enExample) |
| EP (2) | EP2421867B1 (enExample) |
| JP (3) | JP5709276B2 (enExample) |
| KR (1) | KR20130009577A (enExample) |
| CN (2) | CN102459270B (enExample) |
| AU (2) | AU2010239396B2 (enExample) |
| BR (1) | BRPI1007737A2 (enExample) |
| CA (2) | CA3025627C (enExample) |
| ES (1) | ES2552805T3 (enExample) |
| WO (1) | WO2010123919A2 (enExample) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102459270B (zh) | 2009-04-20 | 2015-04-29 | 奥斯拜客斯制药有限公司 | Janus激酶3的哌啶抑制剂 |
| EP2481411A1 (en) * | 2011-01-27 | 2012-08-01 | Ratiopharm GmbH | Oral dosage forms for modified release comprising the JAK3 inhibitor tasocitinib |
| US20120195966A1 (en) * | 2011-01-27 | 2012-08-02 | Frank Sievert | Oral dosage form for modified release comprising a jak3 inhibitor |
| EP2675275B1 (en) | 2011-02-14 | 2017-12-20 | The Regents Of The University Of Michigan | Compositions and methods for the treatment of obesity and related disorders |
| US20150291594A1 (en) * | 2012-08-14 | 2015-10-15 | Concert Pharmaceuticals, Inc. | Deuterated Ponatinib |
| CN102875555A (zh) * | 2012-09-27 | 2013-01-16 | 同济大学 | 一种JAK抑制剂Tofacitinib的合成方法 |
| US9481679B2 (en) * | 2012-12-17 | 2016-11-01 | Sun Pharmaceutical Industries Limited | Process for the preparation of tofacitinib and intermediates thereof |
| US9757395B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
| US9757529B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
| WO2014102826A1 (en) * | 2012-12-28 | 2014-07-03 | Glenmark Pharmaceuticals Limited; | The present invention relates to process for the preparation of tofacitinib and intermediates thereof. |
| EP2943489B1 (en) | 2013-01-09 | 2018-04-11 | Concert Pharmaceuticals Inc. | Deuterated momelotinib |
| LT2945939T (lt) | 2013-01-15 | 2020-07-27 | Incyte Holdings Corporation | Triazolkarboksamidai ir piridinkarboksamido junginiai, naudotini kaip pim kinazės inhibitoriai |
| CN103965114B (zh) * | 2013-01-28 | 2016-01-06 | 苏州泽璟生物制药有限公司 | 氘代的苯基氨基嘧啶化合物以及包含该化合物的药物组合物 |
| CN103073552B (zh) * | 2013-02-05 | 2015-08-12 | 华润赛科药业有限责任公司 | 一种无定型枸橼酸托法替尼的制备方法 |
| JP6041823B2 (ja) | 2013-03-16 | 2016-12-14 | ファイザー・インク | トファシチニブの経口持続放出剤形 |
| US10149823B2 (en) | 2013-04-30 | 2018-12-11 | Otitopic Inc. | Dry powder formulations and methods of use |
| WO2014179734A1 (en) | 2013-05-02 | 2014-11-06 | The Regents Of The University Of Michigan | Deuterated amlexanox |
| WO2014195978A2 (en) * | 2013-06-05 | 2014-12-11 | Msn Laboratories Limited | PROCESS FOR THE PREPARATION OF (3R,4R)-4-METHYL-3-(METHYL-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL-AMINO)-ß-OXO-1-PIPERIDINEPROPANENITRILE AND ITS SALTS |
| CN104447751A (zh) * | 2013-09-16 | 2015-03-25 | 天津市汉康医药生物技术有限公司 | 一种托法替尼化合物 |
| CN104447752A (zh) * | 2013-09-16 | 2015-03-25 | 天津市汉康医药生物技术有限公司 | 一种托法替尼水合物及其制备方法 |
| CN104292231B (zh) * | 2013-09-17 | 2016-11-30 | 广东东阳光药业有限公司 | 一种枸橼酸托法替尼的制备方法 |
| CN104513248B (zh) * | 2013-09-30 | 2019-05-24 | 重庆医药工业研究院有限责任公司 | 一种托法替尼中间体的纯化方法 |
| CN105873931B (zh) * | 2013-10-08 | 2018-10-16 | 广东东阳光药业有限公司 | 托法替布柠檬酸盐 |
| CN103819474A (zh) * | 2013-11-04 | 2014-05-28 | 湖南华腾制药有限公司 | 一种托法替尼的制备方法 |
| BR112015025543B1 (pt) | 2013-12-09 | 2020-11-03 | Unichem Laboratories Limited | processo para a preparação de (3r,4r)-(1-benzil-4- metilpiperidina-3-il)-metilamina e compostos intermediários |
| EA201691582A1 (ru) | 2014-02-07 | 2017-01-30 | Оспекс Фармасьютикалз, Инк. | Новые фармацевтические препараты |
| US20150284327A1 (en) * | 2014-04-04 | 2015-10-08 | Auspex Pharmaceuticals, Inc. | Oxindole inhibitors of tyrosine kinase |
| CN104710346B (zh) * | 2015-02-15 | 2017-04-12 | 江苏苏利精细化工股份有限公司 | 一种合成顺式‑1‑苄基‑3‑甲氨基‑4‑甲基‑哌啶的方法 |
| EP3078665A1 (en) * | 2015-04-10 | 2016-10-12 | OLON S.p.A. | Efficient method for the preparation of tofacitinib citrate |
| WO2016192563A1 (zh) * | 2015-05-29 | 2016-12-08 | 南京明德新药研发股份有限公司 | Janus激酶抑制剂 |
| AR105967A1 (es) | 2015-09-09 | 2017-11-29 | Incyte Corp | Sales de un inhibidor de pim quinasa |
| WO2017059251A1 (en) | 2015-10-02 | 2017-04-06 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
| CN105440039A (zh) * | 2015-11-24 | 2016-03-30 | 山东淄博新达制药有限公司 | 枸橼酸托法替布的合成方法 |
| EP3407974A4 (en) | 2016-01-29 | 2019-08-28 | The Regents Of The University Of Michigan | Amlexanox Analogs |
| CN105884781B (zh) * | 2016-04-18 | 2018-04-20 | 山东罗欣药业集团股份有限公司 | 一种枸橼酸托法替布的制备方法 |
| CN106188064A (zh) * | 2016-07-07 | 2016-12-07 | 国药集团容生制药有限公司 | 一种N‑甲基‑N‑((3R，4R)‑4‑甲基吡啶‑3‑基)‑7H‑吡咯并[2,3‑d]嘧啶‑4‑胺的制备方法 |
| CN105949204A (zh) * | 2016-07-25 | 2016-09-21 | 国药集团容生制药有限公司 | 一种N-((3R，4R)-1-苄基-4-甲基吡啶-3-基)-N-甲基-7H-吡咯并[2,3-d]嘧啶-4-胺的制备方法 |
| EP3421455B1 (en) * | 2017-06-29 | 2019-03-27 | F.I.S.- Fabbrica Italiana Sintetici S.p.A. | Improved process for the preparation of chiral 3-amino-piperidins, useful intermediates for the preparation of tofacitinib |
| CN109293682A (zh) * | 2017-07-25 | 2019-02-01 | 重庆医药工业研究院有限责任公司 | 一种托法替布杂质及其制备方法 |
| US10786456B2 (en) | 2017-09-22 | 2020-09-29 | Otitopic Inc. | Inhaled aspirin and magnesium to treat inflammation |
| CN115919780A (zh) | 2017-09-22 | 2023-04-07 | 维克图拉公司 | 含有硬脂酸镁的干粉组合物 |
| CN108358930A (zh) * | 2018-02-05 | 2018-08-03 | 南京法恩化学有限公司 | 一种枸橼酸托法替尼的制备方法 |
| CN109776547A (zh) * | 2019-03-22 | 2019-05-21 | 北京新领先医药科技发展有限公司 | 一种枸橼酸托法替布的制备方法 |
| EP4153565A1 (en) * | 2020-05-20 | 2023-03-29 | F. Hoffmann-La Roche AG | Benzylpyridinium reagent for mass spectrometry |
| CN111848496B (zh) * | 2020-07-28 | 2021-10-08 | 湖南华纳大药厂手性药物有限公司 | 一种托法替布中间体胺及其双盐酸盐的制备方法 |
| CN112679508B (zh) * | 2021-03-09 | 2021-08-10 | 正大天晴药业集团南京顺欣制药有限公司 | 一种托法替布中间体的制备方法 |
| WO2023248010A2 (en) | 2022-06-23 | 2023-12-28 | Synovo Gmbh | Targeted modulators of jak3 for treatment of inflammatory and autoimmune diseases |
| US20250102479A1 (en) * | 2023-09-22 | 2025-03-27 | Thermo Finnigan Llc | Method of utilizing deuterium gas for chromatography applications, deuterium gas generator and devices for conservation thereof |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3696884B2 (ja) | 1994-03-25 | 2005-09-21 | アイソテクニカ、インコーポレーテッド | ジュウテリウム化による薬物の効能の増強 |
| US6221335B1 (en) * | 1994-03-25 | 2001-04-24 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| CA2198382A1 (en) * | 1994-09-30 | 1996-04-11 | Novartis Ag | 1-acyl-4-aliphatylaminopiperidine compounds |
| PA8474101A1 (es) * | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
| RS50087B (sr) * | 1998-06-19 | 2009-01-22 | Pfizer Products Inc., | Pirolo (2,3-d) pirimidin jedinjenja |
| US6440710B1 (en) * | 1998-12-10 | 2002-08-27 | The Scripps Research Institute | Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds |
| EP1104760B1 (en) * | 1999-12-03 | 2003-03-12 | Pfizer Products Inc. | Sulfamoylheteroaryl pyrazole compounds as anti-inflammatory/analgesic agents |
| CZ303875B6 (cs) * | 1999-12-10 | 2013-06-05 | Pfizer Products Inc. | Pyrrolo[2,3-d]pyrimidinová sloucenina a farmaceutická kompozice s jejím obsahem |
| EP1134290A3 (en) * | 2000-03-14 | 2004-01-02 | Pfizer Products Inc. | Pharmacophore models for the identification of the CYP2D6 inhibitory potency of selective serotonin reuptake inhibitors |
| EA006153B1 (ru) * | 2000-06-26 | 2005-10-27 | Пфайзер Продактс Инк. | СОЕДИНЕНИЯ ПИРРОЛО[2,3-d]ПИРИМИДИНА В КАЧЕСТВЕ ИММУНОДЕПРЕССАНТОВ |
| US7301023B2 (en) * | 2001-05-31 | 2007-11-27 | Pfizer Inc. | Chiral salt resolution |
| GT200200234A (es) * | 2001-12-06 | 2003-06-27 | Compuestos cristalinos novedosos | |
| TW200413273A (en) * | 2002-11-15 | 2004-08-01 | Wako Pure Chem Ind Ltd | Heavy hydrogenation method of heterocyclic rings |
| EP1572649A2 (en) * | 2002-11-21 | 2005-09-14 | Pfizer Products Inc. | 3-amino-piperidine derivatives and processes for their preparation |
| CA2507392A1 (en) | 2002-11-26 | 2004-06-10 | Pfizer Products Inc. | Method of treatment of transplant rejection |
| WO2005051393A1 (en) | 2003-11-25 | 2005-06-09 | Pfizer Products Inc. | Method of treatment of atherosclerosis |
| MXPA06007002A (es) | 2003-12-17 | 2006-08-31 | Pfizer Prod Inc | Compuestos de pirrolo[2,3-d]pirimidina para tratar rechazo de transplantes. |
| WO2005063251A1 (en) | 2003-12-17 | 2005-07-14 | Pfizer Products Inc. | Modified stent useful for delivery of drugs along stent strut |
| US20050137679A1 (en) * | 2003-12-17 | 2005-06-23 | Pfizer Inc | Modified stent useful for delivery of drugs along stent strut |
| WO2005063318A1 (en) | 2003-12-17 | 2005-07-14 | Pfizer Products Inc. | Stent with therapeutically active drug coated thereon |
| EP1755680A1 (en) | 2004-05-03 | 2007-02-28 | Novartis AG | Combinations comprising a s1p receptor agonist and a jak3 kinase inhibitor |
| WO2006013114A1 (en) | 2004-08-06 | 2006-02-09 | Develogen Aktiengesellschaft | Use of a timp-2 secreted protein product for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome |
| KR20070085433A (ko) | 2004-11-24 | 2007-08-27 | 노파르티스 아게 | Ｊａｋ 저해제들과 ｂｃｒ-ａｂｌ, ｆｌｔ-3, ｆａｋ 또는ｒａｆ 키나제 저해제들 중 하나 이상의 조합물 |
| ATE542535T1 (de) | 2005-05-04 | 2012-02-15 | Develogen Ag | Verwendung von azapaullonen zur vorbeugung und behandlung pankreatischer autoimmunkrankheiten |
| WO2006117212A2 (en) | 2005-05-04 | 2006-11-09 | Develogen Aktiengesellschaft | Use of gsk-3 inhibitors for preventing and treating pancreatic autoimmune disorders |
| WO2006136374A2 (en) | 2005-06-20 | 2006-12-28 | Develogen Aktiengesellschaft | Use of gip and/or vitamin d3 analogues thereof for enhancing stem or progenitor cell differentiation into insulin producing cells |
| US20080033011A1 (en) * | 2005-07-29 | 2008-02-07 | Concert Pharmaceuticals Inc. | Novel benzo[d][1,3]-dioxol derivatives |
| MX2008001334A (es) | 2005-07-29 | 2008-03-24 | Pfizer Prod Inc | Derivados de pirrolo [2,3-d]pirimidina, sus intermedios y sintesis. |
| US7750168B2 (en) * | 2006-02-10 | 2010-07-06 | Sigma-Aldrich Co. | Stabilized deuteroborane-tetrahydrofuran complex |
| GB0605691D0 (en) * | 2006-03-21 | 2006-05-03 | Novartis Ag | Organic Compounds |
| WO2008029237A2 (en) | 2006-09-05 | 2008-03-13 | Pfizer Products Inc. | Combination therapies for rheumatoid arthritis |
| US20090182035A1 (en) | 2007-04-11 | 2009-07-16 | Alcon Research, Ltd. | Use of a combination of olopatadine and cilomilast to treat non-infectious rhinitis and allergic conjunctivitis |
| US20080254029A1 (en) * | 2007-04-11 | 2008-10-16 | Alcon Research, Ltd. | Use of an Inhibitor of TNFa Plus an Antihistamine to Treat Allergic Rhinitis and Allergic Conjunctivitis |
| EP2175858B1 (en) | 2007-07-11 | 2014-09-10 | Pfizer Inc. | Pharmaceutical compositions and methods of treating dry eye disorders |
| JP5492194B2 (ja) | 2008-05-13 | 2014-05-14 | アイアールエム・リミテッド・ライアビリティ・カンパニー | キナーゼ阻害剤としての縮合窒素含有ヘテロ環およびその組成物 |
| HUE028347T2 (en) | 2008-06-10 | 2016-12-28 | Abbvie Inc | Tricyclic compounds |
| CN102459270B (zh) | 2009-04-20 | 2015-04-29 | 奥斯拜客斯制药有限公司 | Janus激酶3的哌啶抑制剂 |
-
2010
- 2010-04-20 CN CN201080025178.1A patent/CN102459270B/zh active Active
- 2010-04-20 CN CN201510171918.7A patent/CN104817561B/zh active Active
- 2010-04-20 EP EP10767652.0A patent/EP2421867B1/en active Active
- 2010-04-20 WO PCT/US2010/031773 patent/WO2010123919A2/en not_active Ceased
- 2010-04-20 CA CA3025627A patent/CA3025627C/en active Active
- 2010-04-20 EP EP15002523.7A patent/EP3026052A1/en not_active Withdrawn
- 2010-04-20 AU AU2010239396A patent/AU2010239396B2/en active Active
- 2010-04-20 BR BRPI1007737-5A patent/BRPI1007737A2/pt not_active IP Right Cessation
- 2010-04-20 ES ES10767652.0T patent/ES2552805T3/es active Active
- 2010-04-20 KR KR1020117026990A patent/KR20130009577A/ko not_active Ceased
- 2010-04-20 US US12/763,858 patent/US8299084B2/en active Active
- 2010-04-20 JP JP2012506006A patent/JP5709276B2/ja active Active
- 2010-04-20 CA CA2759026A patent/CA2759026C/en active Active
-
2012
- 2012-09-26 US US13/627,747 patent/US8962638B2/en active Active
-
2015
- 2015-01-14 US US14/596,784 patent/US9493469B2/en active Active
- 2015-02-26 JP JP2015037398A patent/JP5932080B2/ja active Active
-
2016
- 2016-04-20 JP JP2016084849A patent/JP6145534B2/ja active Active
- 2016-07-18 AU AU2016206214A patent/AU2016206214B2/en active Active
- 2016-08-05 US US15/229,267 patent/US9856261B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012524085A5 (enExample) | ||
| JP2012503010A5 (enExample) | ||
| JP2010507585A5 (enExample) | ||
| JP2009511481A5 (enExample) | ||
| ES2633658T3 (es) | Moduladores 2-oxo-1,2-dihidro-quinolina de la función inmunitaria | |
| JP2009539863A5 (enExample) | ||
| US9526711B2 (en) | Biphenyl-3-carboxylic acid modulators of beta-3-adrenoreceptor | |
| US9260424B2 (en) | 4,6-diaminopyrimidine stimulators of soluble guanylate cyclase | |
| US20080280886A1 (en) | Substituted ureas | |
| JP2010512343A5 (enExample) | ||
| US20100087455A1 (en) | Substituted xanthine compounds | |
| WO2010054158A2 (en) | Steroid modulators of glucocorticoid receptor | |
| US20100291151A1 (en) | 1-methylpyrazole modulators of substance p, calcitonin gene-related peptide, adrenergic receptor, and/or 5-ht receptor | |
| US20180016244A1 (en) | Deuterium-substituted oxadiazoles | |
| US20110082151A1 (en) | Sulfonylurea modulators of endothelin receptor | |
| CA2631581A1 (en) | Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity | |
| JP2016529228A5 (enExample) | ||
| US20090247628A1 (en) | Substituted phenylcyclohexylglycolates | |
| JP2018507210A5 (enExample) | ||
| US20090005431A1 (en) | Substituted pyrrolidines | |
| US20100143287A1 (en) | Trifluoromethylphenyl modulators of calcium-sensing receptor | |
| RU2024129873A (ru) | Дейтерированные аналоги пиррольных ингибиторов erk, их синтез и промежуточные соединения | |
| US20100284970A1 (en) | Benzimidazole modulators of h1 receptor and/or ns4b protein | |
| US20100120756A1 (en) | Phenothiazine modulators of h1 receptors | |
| JPWO2020198529A5 (enExample) |